Furthermore, N-Myc deregulation is implicated in other cancers like medulloblastoma, neuroendocrine prostate cancer, rhabdomyosarcoma, and AML 41, warranting further investigation into N78's efficacy against these N-Myc-driven malignancies. Here, MYCN is linked to medulloblastoma.